跳至主要内容
临床试验/NCT02652299
NCT02652299已完成不适用

Fibrocytes in Early and Longstanding Rheumatoid Arthritis

Odense University Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
Fibrocytes in the peripheral blood.

研究概览

简要总结

This study will focus on a rare cell population called fibrocytes in peripheral blood and synovial tissue in Rheumatoid Arthritis (RA). One group of patients with early RA and one group with long-standing RA. Both groups will be followed for 6 months.

After informed and written consent a control groups is also formed: One for synovial biopsies for patients undergoing a routine arthroscopy, where a peripheral blood sample is also taken.

The hypothesis is that fibrocytes are present in the blood and synovial tissue in RA. Patients with early and long-standing RA have higher concentrations of fibrocytes in peripheral blood and synovial tissue compared to a control groups. Levels of fibrocytes in peripheral blood and synovial tissue are correlated with RA disease activity measures and imaging findings.

详细描述

The intimal lining of a synovial joint consists of unique cells called fibroblast-like synoviocytes (FLS cells) with interspersed macrophage-like synoviocytes. In the healthy joint macrophage-like synoviocytes are implicated in the innate immune defence and support adaptive immunity, while FLS cells function to regulate the release of nutrients and molecules, including hyaluronan, into the joint cavity.

Rheumatoid arthritis (RA) is a chronic systemic disease with autoimmune traits, which primarily affects synovial joints. The intimal lining of the synovium expands and exhibits characteristics of unregulated growth and loss of contact inhibition. The expanding synovium degrades cartilage and erodes into the bone at the cartilage-bone interface, creating the hallmark of RA, the joint erosion.

The RA FLS cell, has a markedly different phenotype than the healthy cell, and plays a key role in the destructive process by the release of pro-inflammatory cytokines and matrix destructive enzymes. FLS cells expand during the joint destructive process, however, there is minimal mitotic activity. The origin of the expanding FLS population is therefore uncertain.

Possible explanations to this phenomenon could be decreased senescence, migration of mesenchymal stem cells from the circulation, epithelial to mesenchymal cell-transition or expansion of a stem cell pool in the synovium. FLS precursors could also migrate to the synovium through pores in cortical bone, as has been demonstrated in mice with collagen-induced arthritis. In a murine model, it has further been shown that RA FLS cells can spread via the systemic circulation from one joint and attack previously unaffected joints.

A possible FLS cell precursor has been identified in peripheral blood and called fibrocytes. Fibrocytes are spindle-shaped cells that express surface receptors of both stromal and hematopoietic cells. The fibrocytes are a rare (~0.5% of leukocytes) population of bone marrow derived mesenchymal progenitor cells. A combination of markers that distinguish fibrocytes from monocytes, macrophages and fibroblasts has been described. In vitro circulating human peripheral blood mononuclear cells and monocytes (CD14+) can differentiate into fibrocytes. Fibrocytes can differentiate in vitro along multiple mesenchymal lineages into adipocytes, chondrocytes, myofibroblasts and osteoblasts. It is unknown which differentiation pathway occurs in vivo or if multiple differentiation profiles can occur .

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with newly diagnosed RA (according to 2010 classification criteria) who have been diagnosed ≤ 6 months, and who have at least one swollen joint in hands/fingers.
  • Patients with longstanding RA (>5 years duration).
  • Ability and willingness to give written informed consent and to meet the requirements of this protocol.
  • Exclusion criteria
  • Age < 18 years.
  • Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis or primary vasculitis.
  • History of or current inflammatory joint disease other than RA (e.g. gout, reactive arthritis, psoriatic arthritis, spondyloarthropathy, Lyme disease).
  • Allergy to local aesthetics.
  • Hereditary or acquired (e.g. Anticoagulant Treatment, apart from low dose aspirin) coagulation abnormality.
  • Prednisolone above 7.5 mg/day
  • Skin pathology at site of joint biopsy.
  • Obesity, BMI >
  • Functional class IV as defined by the criteria for classification of functional status in RA.
  • Heart failure (NYHA class III/IV), immunodeficiency, current or past malignant disease (except for non-melanoma skin cancer), recurrent or chronic infections (viral, fungal or bacterial), inflammatory bowel disease, myeloproliferative disorder or other bone marrow disease.
  • Severe nervous system, liver, pulmonary, renal or endocrine disease (including Type 1 diabetes, stable type 2 diabetes is allowable).
  • Major surgery within 8 weeks. Laboratory exclusion Criteria Platelet count <100 x 109 /L or Haemoglobin <5 mmol/L or White blood cells <3 x 109/L or estimated Glomerular Filtration Rate (eGFR) <60.

排除标准

  • 未提供

结局指标

主要结局

Fibrocytes in the peripheral blood.

时间窗: 6 months

Compare level of fibrocytes (Fibrocytes/uL) in peripheral blood between the group of healthy controls and patients with early and long-standing RA. Compare level of fibrocytes (Fibrocytes/uL) at start of observation to end of observation in both RA groups.

次要结局

  • Interstitial lung disease and fibrocyte level.(6 months)
  • Fibrocytes and RA disease activity by imaging, and synovial tissue analysis.(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Søren Andreas Just

MD

Odense University Hospital

研究点 (1)

Loading locations...

相似试验